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Abstract 
Background: High-density lipoprotein cholesterol (HDL-C), an established risk marker for atherosclerotic 
cardiovascular disease (CVD), has been shown to be inversely and independently associated with incident 
hypertension. Paraoxonase-1 (PON-1) is an HDL-bound esterase enzyme which is associated with CVD, 
but its relationship with incident hypertension has not been previously investigated. We aimed to evaluate 
the prospective association between PON-1 and hypertension risk. 
Methods: PON-1 arylesterase activity was measured in serum at baseline in 3,988 participants without 
pre-existing hypertension in the Prevention of Renal and Vascular End-stage Disease (PREVEND) 
prospective population-based study. During a median follow-up of 10.7 years, 1,206 participants 
developed hypertension.  
Results: In age- and sex-adjusted analysis, the hazard ratio (95% CI) for incident hypertension per 1 
standard deviation increase in PON-1 was 1.01 (0.96 to 1.07; p=0.656), which remained non-significant  
after adjustment for several established hypertension risk factors and other potential confounders (0.99, 
0.93 to 1.05; p=0.764). The association was also non-existent on further adjustment for HDL-C (1.00 
(0.94 to 1.06; p=0.936) and did not importantly vary across several clinical subgroups. In analyses in the 
same set of participants, HDL-C was continuously inversely and independently associated with 
hypertension risk; the association persisted after further adjustment for PON-1 activity and was not 
modified by PON-1 activity.  
Conclusions: In this Caucasian cohort of men and women, HDL-C, but not its anti-oxidant constituent - 
PON-1, is inversely, continuously and independently associated with future risk of hypertension. The 
association is independent of and not modified by PON-1. 
 
Keywords: paraoxonase-1; HDL cholesterol; antioxidant; risk factor; hypertension 
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1. Introduction 
High-density lipoprotein cholesterol (HDL-C), which is included in the commonly used cardiovascular 
risk algorithms,1-4  is an important risk factor for atherosclerotic cardiovascular disease (CVD).5 A 
number of studies have also shown HDL-C to be inversely and independently associated with the risk of 
hypertension6-9 which is the most common modifiable risk factor for CVD10 and is a leading cause of 
death globally.11 Indeed, hypertension and CVD share common antecedent risk factors (such as obesity, 
diabetes, and dyslipidaemia)12 and pathophysiological pathways such as oxidative stress and 
inflammation.13-15  
Paraoxonase-1 (PON-1), an HDL-bound esterase enzyme with well-established antioxidant and anti-
inflammatory properties,16-19 has been shown to be associated with CVD risk; though the evidence 
suggests that the association is partly dependent on HDL-C  levels.20 Since oxidative stress is known to 
play a central role in the pathogenesis of hypertension,21 the underlying mechanism by which HDL may 
contribute to lowering the risk of incident hypertension is via its antioxidant properties. Considerable 
evidence suggests that the ability of the HDL to counter oxidative stress (via inhibition of oxidative 
modification of low-density lipoproteins) have been proposed to be largely attributable to its PON-1 
component.19, 22, 23  Given the broad body of evidence on the close relationship between HDL and PON-1, 
it is plausible to hypothesize that PON-1 may also be related to the risk of hypertension. Remarkably, 
little is known about the association between PON-1 and hypertension. Majority of published studies have 
been based on animal models24 or cross-sectional data in humans25, 26 Though low circulating PON-1 
activity has been observed in patients with hypertension27, the nature of the relationship between PON-1 
and hypertension is also unclear. Whilst findings from some of these studies have suggested a protective 
association of PON-1 on hypertension risk,25, 26 a causal relationship between PON-1 and blood pressure 
has been suggested in other reports.24, 28 It is also unknown if higher PON-1 activity is associated with an 
attenuated risk of hypertension among apparently healthy populations. In this context, our primary 
objective was to assess the nature and magnitude of the prospective association between serum PON-1 
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activity and future risk of hypertension in a Caucasian population who were apparently free from 
hypertension and other pre-existing diseases at baseline. A secondary objective was to re-evaluate the 
expected inverse association of serum HDL-C concentration with risk of incident hypertension in the 
same set of participants, and to evaluate if the association is independent or modified by PON-1 activity. 
 
2. Methods 
The STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) guidelines for 
reporting observational studies in epidemiology was used during the conduct of this study (Appendix 
1).29  
 
2.1. Study Design and participants  
The current analysis employed the Prevention of Renal and Vascular End-stage Disease (PREVEND) 
study. It is a prospective population-based investigation of albuminuria, renal and cardio-metabolic 
disease in a large cohort recruited from a general population setting.30 The study was began in 1997 and 
involved recruitment of participants aged 28-75 years who were inhabitants of the city of Groningen in 
The Netherlands. The details of the study design and recruitment processes have been reported 
elsewhere.31, 32 Baseline measurements were performed between 1997 and 1998 in a cohort comprising of 
8,592 participants. In the current analysis, we excluded participants with hypertension, CVD, renal 
disease, or malignancy at baseline; which left 3,988 participants with non-missing information on PON-1 
activity, HDL-C concentrations, relevant covariates, and incident hypertension. The local medical ethics 
committee of the University Medical Center Groningen approved the protocol for the PREVEND study 
and it was carried out in accordance with the Declaration of Helsinki. Written informed consent was 
provided by all participants. 
 
 
 
5 
 
2.2. Risk factor assessment 
During two outpatient visits, baseline data were collected on demographics, physical measurements 
(including anthropometrics), prevalent medical conditions, and use of medications. Additional 
information on use of medications was collected using data from pharmacy registries of all community 
pharmacies in the city of Groningen. Blood pressure was assessed on the right arm whiles the subject was 
in the supine position; measurements were done every minute for 10 and 8 min on visit 1 and 2 
respectively, using an automatic device (Dinamap XL Model 9300; Johnson-Johnson Medical, Tampa, 
FL). The mean blood pressure of the last two readings of both visits was recorded. Venous blood samples 
were taken from participants between 08:00 and 10.00 hours in the morning after an overnight fast and 15 
minutes of rest. Plasma samples were centrifuged at 4 ºC. The collected serum samples were stored at -80 
ºC until analysis. The enzymatic activity of serum PON-1 was measured as its arylesterase activity, i.e. as 
the rate of hydrolysis of phenyl acetate into phenol, as described in previous papers.20, 33 The inter-assay 
CV was 8%. It has been shown that arylesterase activity measured with this assay is positively correlated 
PON-1 enzymatic activity toward paraoxon.34 Total cholesterol and plasma glucose were measured by a 
dry chemistry method (Eastman Kodak, Rochester, New York). HDL-C was measured by a homogeneous 
method (direct HDL, Aeroset System; Abbott Laboratories, Abbott Park, Illinois). Standard methods were 
used to measure apolipoproteins (Apo) A-1 and B, high sensitivity C-reactive protein (hsCRP), serum 
creatinine, and serum cystatin C.35-39 The mean of two 24-hour urine collections was used for estimating 
urinary albumin excretion (UAE). Urinary albumin was determined by nephelometry (BNII; Dade 
Behring Diagnostic, Marburg, Germany). Estimated glomerular filtration rate (eGFR), was calculated 
using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) combined creatinine-cystatin 
C equation.40 Insulin resistance was estimated according to the homeostasis model assessment of insulin 
resistance (HOMA-IR) (the product of fasting glucose [mmol/l] and insulin [units/ml] divided by the 
constant 22.541).  
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2.3. Ascertainment of incident hypertension 
Development of hypertension during follow-up was used as the primary outcome for this study. 
Incident hypertension was defined as systolic blood pressure (SBP) of ≥140 mm Hg, a diastolic BP of ≥90 
mm Hg, or the use of antihypertensive medication, in accordance with recommendations from the 
Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure.42 We also used this definition to ensure consistency with previous reports6-9 and which would 
enhance comparison. Data on the use of antihypertensive medications were ascertained by administration 
of questionnaires at each examination and from community pharmacies in the city of Groningen, which 
covers complete information on drug use in 95% of PREVEND participants.  
 
2.4. Statistical analyses 
Baseline characteristics of study participants were presented overall and according to the development 
of hypertension during follow-up. Normally distributed variables were presented as mean (standard 
deviation, SD) and skewed variables as median (IQR, interquartile range). Skewed variables (such as 
UAE, HOMA-IR, and hsCRP) were natural logarithm (loge) transformed to achieve approximately 
normal distributions before the main analysis. Age- and sex-adjusted cross-sectional associations of 
serum PON-1 activity with risk markers for hypertension were assessed. Cox proportional hazards models 
were used to assess to estimate hazard ratios (HR) of serum PON-1 activity with incident hypertension 
risk, after confirmation of the proportionality of hazards assumptions.43 Hazard ratios were calculated per 
1 SD higher serum PON-1 values and by quartiles defined according to the baseline distribution of serum 
PON-1 values. To assess the independence of the association between PON-1 and hypertension risk, HRs 
were calculated with progressive adjustment for (i) age and sex; (ii) other established hypertension factors 
[smoking status, history of diabetes, SBP, total cholesterol, body mass index (BMI), parental history of 
hypertension, alcohol consumption, and eGFR]; (iii) other potential confounders (UAE, HOMA-IR, and 
hsCRP); and (iv) HDL-C. We conducted formal tests of interaction to evaluate if the association was 
modified by age, sex, and other risk markers for hypertension. To put our findings into context, direct 
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comparisons were made to associations of HDL-C with incident hypertension in the same set of 
participants. To assess the shape of the association between HDL-C and hypertension risk, we fitted 
multivariate-adjusted fractional polynomial models. To avoid double counting of the hypertension 
burden, studies of the global and national burden of risk factors now base their data on SBP 
measurements due to the strong correlation between SBP and DBP.44 Moreover, SBP has been considered 
to be a better predictor of health outcomes than DBP.45 Given this, we conducted subsidiary analyses 
which re-assessed the associations of PON-1 and HDL-C with risk of hypertension, as defined by SBP ≥ 
140 mmHg and/or use of antihypertensive medication. To limit potential biases due to pre-existing 
disease, we also conducted subsidiary analysis which excluded participants with type 2 diabetes at 
baseline. Stata version 14 (Stata Corp, College Station, Texas) was employed in all statistical analyses. 
 
3. Results 
3.1. Baseline characteristics and correlates of paraoxonase-1 activity 
Baseline clinical and laboratory characteristics of the whole cohort and comparison of individuals who 
developed new-onset hypertension versus individuals who remained free of hypertension are shown in 
Table 1. The mean age of overall participants at baseline was 45 (SD 11) years and the mean (SD) for 
PON-1 was 56.4 (18.0) U/L. Individuals who developed hypertension during follow-up were more likely 
to be male, older, obese, have higher BP, have diabetes, and more likely to be smokers at study entry 
compared with those who did not develop hypertension. Levels of total cholesterol, non-HDL-C, Apo B, 
glucose, hsCRP, and UAE were higher at baseline in individuals who developed hypertension compared 
with those who did not develop hypertension. Baseline HDL-C concentrations were lower in those who 
developed incident hypertension versus those who did not develop incident hypertension, but PON-1 
activity was not significantly different between the groups. PON-1 was weakly correlated with waist-to-
hip ratio, total cholesterol, HDL-C, Apo A-1, glucose, and hsCRP. The strongest correlations were 
observed with HDL-C (r = 0.16), Apo A-1 (r=0.16), and total cholesterol (r = 0.10). Baseline PON-1 
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values were significantly lower in men than in women, and were higher in current alcohol consumers 
compared with non-consumers (Table 2).  
 
3.2. Paraoxonase-1 activity and risk of incident hypertension 
During a median (IQR) follow-up of 10.7 (5.5-11.6) years, 1,206 subjects developed first-onset 
hypertension. In age and sex adjusted analysis, the HR for incident hypertension per 1 SD increase in 
PON-1 was 1.01 (95% CI, 0.96 to 1.07; p=0.656); which remained non-significant in analyses further 
adjusted for several established hypertension risk factors (smoking status, history of diabetes, SBP, total 
cholesterol, BMI, parental history of hypertension, alcohol consumption, and eGFR) and additional 
adjustment for loge UAE, loge HOMA-IR, and loge hsCRP. This association remained consistently absent 
after additional adjustment for HDL-C (HR, 1.00; 95% CI, 0.94 to 1.06; p=0.936). Substituting total 
cholesterol and HDL-C for apolipoproteins B and A-1 respectively resulted in similar associations (data 
not shown). The associations were also unaltered when total cholesterol was substituted with non-HDL-C. 
The non-significant associations were maintained in analyses by quartiles of the baseline distribution of 
PON-1 values (Table 3). The association was not modified by any clinically relevant characteristic 
(Appendix 2). In a subsidiary analysis with incident hypertension now defined as SBP ≥ 140 mmHg 
and/or use of antihypertensive medication, the HRs remained similar (Appendix 3). 
 
3.3. HDL-C and risk of incident hypertension 
In fitting fractional polynomial models, there was a continuous and inverse association of HDL-C with 
risk of hypertension (Figure 1). An age and sex-adjusted model suggested a curvilinear shape; whiles in 
the multivariate-adjusted model, there was a better fit with a linear shape. Comparing the top quartile 
versus bottom quartile of serum HDL-C concentrations, the age and sex adjusted HR for incident 
hypertension was 0.62 (95% CI: 0.52 to 0.74; p<0.001), which was minimally attenuated to 0.76 (95% 
CI: 0.63 to 0.92; p=0.005) following further adjustment for several established risk factors. The 
association remained consistent on further adjustment for loge UAE, loge HOMA-IR, and loge hsCRP and 
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was unchanged on additional adjustment for PON-1(HR, 0.80; 95% CI: 0.66 to 0.98; p=0.030) (Table 4). 
Substituting total cholesterol for Apo B or non-HDL-C yielded essentially similar associations. The 
associations persisted when incident hypertension was defined as SBP ≥ 140 mmHg and/or use of 
antihypertensive medication (Appendix 4). The associations also remained similar in analyses that 
excluded participants with type 2 diabetes at baseline (Appendix 5). Except for evidence of effect 
modification by SBP (p for interaction = 0.028), the association between HDL-C and incident 
hypertension was not significantly modified by other clinically relevant characteristics including PON-1. 
A strong inverse association was observed in subjects with lower SBP (< 119 mmHg) compared to a 
modest association in subjects with higher SBP (≥ 119 mmHg) (Figure 2).  
 
4. Discussion 
4.1. Key findings 
To our knowledge, this is the first prospective study to date to examine the association of PON-1 with 
incident hypertension in a general population setting. In this well characterized and established cohort 
without histories of CVD and hypertension at baseline, we observed no association between baseline 
PON-1 activity and future risk of hypertension. The null association was not modified by any clinically 
relevant characteristic including HDL-C. In the same set of participants, we observed a continuous 
decrease in hypertension risk with increasing levels of HDL-C. Further large-scale studies are however 
required to determine whether a curvilinear or linear shape would better describe the HDL-C-
hypertension relationship. The association remained independent of and was not modified by serum PON-
1 activity. The association also remained persistent when incident hypertension was defined as SBP ≥ 140 
mmHg and/or use of antihypertensive medication or when participants with a prevalent history of type 2 
diabetes were excluded. 
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4.2. Comparison with previous studies 
Although a number of population-based cohort studies have consistently shown serum PON-1 activity 
to be inversely associated with the risk of CVD; to our knowledge, the prospective association of PON-1 
with the risk of incident hypertension has not been previously investigated. Findings from this large-scale 
prospective cohort study provide novel evidence that serum PON-1 is not associated with the future risk 
of hypertension. Although our findings of an independent and inverse association between HDL-C and 
incident hypertension are consistent with findings of previous population-based studies,6-9 our analyses 
also provide relevant findings that have not been addressed in these previous studies. First, the association 
was independent of several confounders as well as of PON-1. Second, except for SBP, the association 
was not modified by PON-1 or any of the clinical relevant characteristics assessed. Finally, our subsidiary 
analyses in which hypertension was based on only SBP and/or use of antihypertensive medication, 
provided results which were similar to findings reported in the main analyses. 
 
4.3. Possible explanations for findings  
Factors such as endothelial dysfunction, inflammation and oxidative stress have been implicated in the 
pathophysiology of hypertension.13-15 Lipids have been suggested to play a role in the development of 
hypertension, but the biological mechanisms involved in this process are not very well understood. 
Whereas lipids and lipoprotein parameters such as total cholesterol, low-density lipoprotein (LDL) 
cholesterol, non-HDL-C, triglycerides and apolipoprotein B have been shown to be associated with an 
increased risk of hypertension, HDL-C is protective6-9 as demonstrated in the current analyses. It has been 
postulated that the main underlying mechanism between atherogenic lipid abnormalities or dyslipidemia 
and the development of hypertension is via endothelial dysfunction.46 Long-term toxic exposure of the 
endothelium to the pro-atherogenic lipoprotein fraction may cause dysfunction of the endothelium, which 
results in peripheral vascular resistance, arterial stiffness, or decreased arterial compliance, and 
subsequently leads to elevated BP at rest.6, 7, 47, 48 On the other hand, HDL may be protective of 
hypertension through its antioxidant and anti-inflammatory effects which reduce damage to the blood 
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vasculature.49 HDL also has antithrombotic activities and is able to mop cholesterol present within 
atheromatous arteries.50, 51 PON-1, which has well-known antioxidant and anti-inflammatory properties;16-
19 is an important component of HDL and has its site of action on HDL.52-54 Accumulating evidence 
suggests that the ability of the HDL fraction to prevent LDL oxidation can be attributed to PON-1 
activity. Given the consistent body of evidence on the protective association between HDL-C and cardio-
metabolic outcomes, the finding of a null association between PON-1 and hypertension is unexpected. 
However, we have also recently shown no evidence of an association between PON-1 and type 2 diabetes 
and replicated the inverse independent association between HDL-C and type 2 diabetes using data from 
the PREVEND study.55 The overall data suggest there may be important pathophysiologic differences 
between HDL-C and PON-1 in the pathogenesis of these cardio-metabolic outcomes. There is a 
possibility that these findings might reflect the different HDL subclasses or particle sizes, which appear to 
have differential protective effects on LDL oxidation.56 Furthermore, as measurements of PON-1 in the 
PREVEND study involved prolonged serum storage at -80 ºC, it is also possible the null effect could be 
due to under-estimation of the association due to sample degradation. Indeed, PON-1 values in our 
sample were lower compared with previous studies of PON-1 in subjects with hypertension.25, 26 It has 
however been demonstrated that PON-1 shows no loss of activity after prolonged storage in frozen 
samples and on repeated freeze-thawing over two years. Nevertheless, there might be an approximate loss 
in activity of 20% maximally over seven years.57 There is limited evidence available on the topic and 
therefore further large-scale studies with measurements of these markers are warranted to confirm or 
refute these findings.  
 
4.4. Strengths and limitations 
Several methodological strengths of the current study deserve mention. This is the first comprehensive 
analyses of the observational epidemiological prospective association of PON-1 and HDL with the risk of 
incident hypertension in a single investigation. Participants in the PREVEND study were recruited from a 
general population setting and apart from exclusion of hypertensive individuals at baseline, those with 
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pre-existing diseases such as CVD, renal disease, or malignancy were also excluded at baseline. Analyses 
was comprehensive and robust which included adjustment for a comprehensive set of lifestyle and 
biochemical markers, assessment of any dose-response relationships, evaluation of any evidence of effect 
modification, and several sensitivity analyses. Limitations of the current analyses include the potential for 
residual confounding being an observational study, absence of data on HDL subfractions, the potential 
bias resulting from regression dilution because of the absence of data on repeat measurements of these 
markers, and inability to generalize the findings to other ethnicities.  
 
5. Conclusion 
In a general population cohort of Caucasian men and women, serum HDL-C concentration is 
independently and inversely associated with hypertension risk in a continuous fashion. Notably, PON-1, 
which is the main anti-oxidant constituent of HDL-C, is not associated with future risk of hypertension. 
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Figure 1. Hazard ratios for incident hypertension using multivariate-adjusted fractional polynomials 
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A, Hazard ratios were adjusted for age and sex; B, adjustment in A plus smoking status, history of type 2 
diabetes, systolic blood pressure, total cholesterol, body mass index, parental history of hypertension, 
alcohol consumption, and estimated glomerular filtration rate (as calculated using the Chronic Kidney 
Disease Epidemiology Collaboration combined creatinine-cystatin C equation); HDL-C, high-density 
lipoprotein cholesterol 
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Figure 2. Hazard ratios of HDL-C and incident hypertension risk by several participant level 
characteristics 
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Hazard ratios were adjusted for age, sex, smoking status, history of type 2 diabetes, systolic blood 
pressure, total cholesterol, body mass index, parental history of hypertension, alcohol consumption, and 
estimated glomerular filtration rate (GFR) (as calculated using the Chronic Kidney Disease Epidemiology 
Collaboration combined creatinine-cystatin C equation); CI, confidence interval (bars); HDL-C, high-
density lipoprotein cholesterol; HR, hazard ratio; hs, high-sensitivity; PON-1, paraoxonase-1; UAE, urine 
albumin excretion; *, p value for interaction; cut-offs used for body mass index, systolic blood pressure, 
total cholesterol, PON-1, and hsC-reactive protein are median values. 
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Table 1. Baseline Participant Characteristics Overall and According to the Development of Incident 
Hypertension 
 Overall (N=3,988) 
Mean (SD) or median 
(IQR) or n (%) 
Without incident 
hypertension (N=2,782) 
Mean (SD) median 
(IQR) or n (%) 
With incident 
hypertension (N=1,206) 
Mean (SD) or median 
(IQR) or n (%) 
p valuea 
     
Serum paraoxonase-1 (U/L) 56.4 (18.0) 56.6 (17.9) 55.9 (18.1) 0.254 
     
Questionnaire     
Males 1,790 (44.9) 1,188 (42.7) 602 (49.9) < 0.001 
Age at survey (years) 45 (11) 43 (10) 50 (10) < 0.0001 
History of type 2 diabetes 19 (0.5) 9 (0.3) 10 (0.8) 0.033 
Smoking     
    Current 1,364 (34.2) 941 (33.8) 423 (35.1)  
    Former 1,351 (33.9) 914 (32.9) 437 (36.2) 0.012 
    Never 1,273 (31.9) 927 (33.3) 346 (28.7)  
Alcohol consumers 3,121 (78.2) 2,216 (79.7) 904 (75.0) 0.001 
Parental history of hypertension 1,185 (29.7) 807 (29.0) 378 (31.3) 0.138 
     
Physical measurements     
BMI (kg/m2) 25 (4) 25 (3) 26 (4) < 0.0001 
WHR 0.86 (0.09) 0.85 (0.08) 0.88 (0.09) < 0.0001 
SBP (mmHg) 119 (11) 116 (10) 125 (10) < 0.0001 
DBP (mmHg) 70 (7) 68 (7) 74 (7) < 0.0001 
     
Lipid, metabolic, inflammatory, 
and renal markers 
    
Total cholesterol (mmol/l) 5.48 (1.11) 5.35 (1.07) 5.77 (1.14) < 0.0001 
HDL-cholesterol (mmol/l) 1.38 (0.40) 1.41 (0.40) 1.32 (0.41) < 0.0001 
Non-HDL-cholesterol (mmol/l) 4.10 (1.19) 3.94 (1.14) 4.45 (1.24) < 0.0001 
Apo A-1 (g/l) 1.40 (0.30) 1.40 (0.30) 1.39 (0.30) 0.138 
Apo B (g/l) 0.98 (0.30) 0.95 (0.29) 1.07 (0.30) < 0.0001 
Glucose (mmol/l) 4.63 (0.87) 4.55 (0.71) 4.82 (1.13) < 0.0001 
Fasting insulin (units/ml) 7.1 (5.1-10.2) 6.8 (4.9-9.6) 7.8 (5.5-11.6) < 0.0001 
HOMA-IR 1.43 (0.99-2.12) 1.36 (0.96-1.94) 1.65 (1.10-2.50) < 0.0001 
hsCRP (mg/l) 0.95 (0.43-2.30) 0.86 (0.38-2.00) 1.29 (0.58-2.87) < 0.0001 
eGFR (ml/min/1.73 m2) 92.3 (14.0) 93.7 (13.5) 88.9 (14.3) < 0.0001 
UAE (mg/24 hours) 8.04 (5.86-12.45) 7.62 (5.72-11.48) 9.18 (6.38-15.55) < 0.0001 
 
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate (as calculated using the Chronic Kidney 
Disease Epidemiology Collaboration combined creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; HOMA-IR, 
homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; SBP, systolic blood 
pressure; UAE, urinary albumin excretion; WHR, waist-to-hip ratio 
a, employed a two-sample t-tests for a difference in means for continuous variables and a chi square test for categorical variables 
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Table 2. Cross-sectional correlates of paraoxonase-1 
 
Partial correlation 
r (95% CI)a 
Absolute difference (95% CI) in PON-1 activity 
per 1 SD higher or compared to reference category 
of correlateb 
   
Serum paraoxonase-1 (U/L) - - 
   
Sex   
    Female - Ref 
    Male - -3.07% (-4.18, -1.95)*** 
   
Questionnaire   
Age at survey (years) -0.05 (-0.08, -0.02)** -0.91% (-1.46, -0.35)* 
History of type 2 diabetes   
    No - Ref 
    Yes - -6.02% (-14.11, 2.07) 
Smoking status   
    Non-smokers - Ref 
    Current and former smokers - -0.41% (-1.61, 0.78) 
Alcohol consumption   
    Non-consumers - Ref 
    Current consumers - 3.21% (1.85, 4.57)*** 
Parental history of hypertension   
    No - Ref 
    Yes - -0.51% (-1.74, 0.71) 
   
Physical measurements   
BMI (kg/m2) -0.02 (-0.05, 0.01) -0.37% (-0.94, 0.19) 
WHR -0.04 (-0.07, -0.01)*** -0.88% (-1.62, -0.13)* 
SBP (mmHg) 0.05 (0.02, 0.08) 0.98% (0.37, 1.59)* 
DBP (mmHg) 0.04 (0.00, 0.07) 0.71% (0.10, 1.31)* 
   
Lipid, metabolic, inflammatory, and renal markers   
Total cholesterol (mmol/l) 0.10 (0.07, 0.13)*** 1.95% (1.6, 2.53)*** 
HDL-cholesterol 0.16 (0.13, 0.19)*** 3.28 (2.67, 3.89)*** 
Non-HDL-cholesterol (mmol/l) 0.04 (0.01, 0.07) 0.81% (0.21, 1.40)* 
Apo A-1 (g/l) 0.16 (0.13, 0.19)*** 3.05% (2.47, 3.63)*** 
Apo B (g/l) 0.02 (-0.01, 0.05) 0.45 (-0.13, 1.04) 
Glucose (mmol/l) -0.05 (-0.08, -0.02)*** -0.98% (-1.56, -0.41)** 
Loge Fasting insulin (units/ml) 0.03 (0.00, 0.06) 0.57% (0.01, 1.12)* 
Loge HOMA-IR 0.02 (-0.02, 0.05) 0.28% (-0.29, 0.84) 
Loge hsCRP (mg/l) -0.03 (-0.06, -0.00)* -0.60% (-1.16, -0.04)* 
eGFR (ml/min/1.73 m2) 0.01 (-0.02, 0.04) 0.22% (-0.46, 0.90) 
Loge UAE (mg/24 hours) 0.02 (-0.01, 0.05) 0.30% (-0.26, 0.86) 
 
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate (as calculated using the Chronic Kidney 
Disease Epidemiology Collaboration combined creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; HOMA-IR, 
homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; Ref, reference; SD, standard deviation; SBP, 
systolic blood pressure; UAE, urinary albumin excretion; WHR, waist-to-hip ratio 
Asterisks indicate the level of statistical significance: *, p<0.05; **, p<0.01; ***, p<0.001; a, Pearson correlation coefficients between paraoxonase-1 and the row 
variables; b, Absolute change in paraoxonase-1 values per 1 SD increase in the row variable (or for categorical variables, the absolute difference in mean 
paraoxonase-1 values for the category versus the reference) adjusted for age and sex;  
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Table 3. Association of serum paraoxonase-1 activity with incident hypertension 
 
PON-1 activity (U/L) Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
Per 1 SD increase 1,206 / 3,988 1.01 (0.96 to 1.07) 0.656 0.99 (0.93 to 1.05) 0.781 0.99 (0.93 to 1.05) 0.764 1.00 (0.94 to 1.06) 0.936 
Q1 (0.84-43.95) 316 / 997 ref  ref  ref  ref  
Q2 (43.95-53.63) 305 / 997 0.99 (0.84 to 1.16) 0.875 0.89 (0.76 to 1.04) 0.143 0.89 (0.76 to 1.04) 0.155 0.90 (0.77 to 1.06) 0.206 
Q3 (53.64-65.85) 284 / 997 0.96 (0.82 to 1.13) 0.658 0.88 (0.75 to 1.03) 0.116 0.88 (0.75 to 1.04) 0.129 0.91 (0.77 to 1.07) 0.233 
Q4 (65.85-148.68) 301 / 997 1.07 (0.91 to 1.25) 0.433 0.98 (0.83 to 1.15) 0.788 0.98 (0.83 to 1.15) 0.806 1.01 (0.86 to 1.19) 0.919 
 
PON-1, paraoxonase-1; Q, quartile; SD, standard deviation 
Model 1: Age and sex 
Model 2: Model 1 plus smoking status, history of type 2 diabetes, systolic blood pressure, total cholesterol, body mass index, parental history of hypertension, alcohol consumption, and 
estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation) 
Model 3: Model 2 plus loge urinary albumin excretion and loge homeostasis model assessment of insulin resistance, and loge high-sensitivity C-reactive protein 
Model 4: Model 3 plus high-density lipoprotein cholesterol 
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Table 4. Association of serum high-density lipoprotein cholesterol with incident hypertension 
 
Serum HDL-
cholesterol (mmol/l) 
Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
Q1 (0.36-1.08) 396 / 1,010 ref  ref  ref  ref  
Q2 (1.09-1.32) 285 / 984 0.69 (0.59 to 0.80) < 0.001 0.76 (0.65 to 0.89) 0.001 0.76 (0.65 to 0.89) 0.001 0.76 (0.65 to 0.89) 0.001 
Q3 (1.33-1.63) 266 / 1,007 0.60 (0.51 to 0.71) < 0.001 0.74 (0.62 to 0.87) < 0.001 0.76 (0.64 to 0.90) 0.002 0.76 (0.64 to 0.90) 0.002 
Q4 (1.64-3.42) 259 / 987 0.62 (0.52 to 0.74) < 0.001 0.76 (0.63 to 0.92) 0.005 0.80 (0.66 to 0.98) 0.028 0.80 (0.66 to 0.98) 0.030 
 
HDL, high-density lipoprotein; Q, quartile 
Model 1: Age and sex 
Model 2: Model 1 plus smoking status, history of type 2 diabetes, systolic blood pressure, total cholesterol, body mass index, parental history of hypertension, alcohol 
consumption, and estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation) 
Model 3: Model 2 plus loge urinary albumin excretion and loge homeostasis model assessment of insulin resistance, and loge high-sensitivity C-reactive protein 
Model 4: Model 3 plus paraoxonase-1 
 
 
